Madrigal Pharmaceuticals ... (MDGL)
Bid | 430.95 |
Market Cap | 9.64B |
Revenue (ttm) | 515.55M |
Net Income (ttm) | -281.9M |
EPS (ttm) | -12.55 |
PE Ratio (ttm) | -34.46 |
Forward PE | 102.42 |
Analyst | Strong Buy |
Ask | 435.74 |
Volume | 16,702 |
Avg. Volume (20D) | 377,906 |
Open | 435.99 |
Previous Close | 431.21 |
Day's Range | 430.99 - 436.19 |
52-Week Range | 200.63 - 443.00 |
Beta | -1.03 |
About MDGL
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for MDGL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription

3 weeks ago · seekingalpha.com
Madrigal Pharmaceuticals: A High-Paced Launch That Could Grow FurtherRezdiffra's Q2 '25 net sales surged 55% to $212.8M, beating expectations and highlighting strong commercial momentum for Madrigal Pharmaceuticals, Inc. Despite robust revenue growth, Madrigal Pharmace...

1 month ago · seekingalpha.com
Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2025 Earnings Call TranscriptMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants David Soergel - Executive VP & Chief Medical Officer Mardi C. Dier - Execu...

2 months ago · marketwatch.com
Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra ApprovalMadrigal Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Rezdiffra treatment for adults with the liver disease nonci...